We focus on immuno-oncology and precision medicine with a well-balanced oncology portfolio of 17 innovative assets. Currently, CStone has received 16 NDA approvals for its 4 drugs. Among them, GAVRETO^® (pralsetinib), AYVAKIT^® (avapritinib), Cejemly^® (sugemalimab) and TIBSOVO^® (ivosidenib) have been approved by the National Medical Products Administration (NMPA) of China, AYVAKIT^® has been approved by the Taiwan Food and Drug Administration and AYVAKIT^® (avapritinib) and GAVRETO^® (pralsetinib) have been approved by the Department of Health, Hong Kong, China.